The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process
The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments
Women’s wellness initiative promoted preventive healthcare, fitness, and self-care awareness across the Mira Bhayandar community
The six-part webinar series aims to enhance awareness, diagnosis, and management of autoimmune diseases
The once-daily oral therapy is the first and only tyrosine kinase 2 (TYK2) inhibitor approved in the European Union for this indication, marking a significant expansion of its immunology portfolio
Academia-industry partnership to promote indigenous technology commercialization in biotech sector
Initiative aims to strengthen South-South collaboration and capacity building in biomedical research
The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy
The partnership will focus on diabetes and NCD awareness, rare disease screening, and deployment of mobile medical units
The company highlights role of integrated genomics and multi-omics research at the Illumina Multiomics Summit India 2026 held in New Delhi and Bengaluru
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
